Zorn v. U.S. Department of Justice

CourtDistrict Court, District of Columbia
DecidedJanuary 6, 2025
DocketCivil Action No. 2024-3360
StatusPublished

This text of Zorn v. U.S. Department of Justice (Zorn v. U.S. Department of Justice) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zorn v. U.S. Department of Justice, (D.D.C. 2025).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

MATTHEW C. ZORN,

Plaintiff,

v. Case No. 24-cv-03360 (CRC)

U.S. DEPARTMENT OF JUSTICE, DRUG ENFORCEMENT ADMINISTRATION,

Defendants.

MEMORANDUM OPINION AND ORDER

Marijuana legalization has long divided the public. Apparently, it also divides the current

Administration. In October 2022, President Biden directed federal agencies to reevaluate

marijuana’s regulatory status under the Controlled Substances Act. After further deliberations

within the executive branch, the Attorney General signed a notice of proposed rulemaking to

reschedule marijuana and thereby reduce some of the legal restrictions on its use. According to

press reporting, the Attorney General signed the notice over the objections of the Drug

Enforcement Administration (“DEA”). Before the proposed rulemaking was made public,

someone affiliated with a group opposed to rescheduling marijuana posted on social media that

the DEA Administrator had not signed off on it. When asked how he knew of this fact ahead of

the proposal’s release, the person quipped that he had “friends in low places.”

Attorney Matthew Zorn, who represents parties involved in the rulemaking, took those

posts to mean that DEA employees had improperly leaked word of the Administrator’s

recalcitrance. Zorn filed a request under the Freedom of Information Act (“FOIA”) seeking

DEA emails related to any potential leaks, and now seeks a preliminary injunction ordering the

agency to immediately process his request. The Court will deny Zorn’s motion because he has not demonstrated irreparable harm, his request is overly burdensome, and the equities do not

support granting extraordinary relief.

I. Background

A. Rescheduling Marijuana

Under the Controlled Substances Act, substances are classified under one of five

“schedules.” See 21 U.S.C. § 812. Drugs in Schedule I are subject to the strictest regulations

while those in Schedule V are subject to the least strict. See generally id. §§ 821–32, 841–65,

951–71. Marijuana is a Schedule I substance, a classification for drugs that do not have any

“currently accepted medical use in treatment in the United States.” Id. § 812(b)(1)(B), (c).

Lamenting “our failed approach to marijuana,” in 2022, President Biden directed the

Department of Justice and the Department of Health and Human Services to reevaluate the

drug’s classification. Statement from President Biden on Marijuana Reform, The White House

(Oct. 6, 2022), https://perma.cc/L9K7-C26D. About a year and a half later, the Department of

Justice formally proposed rescheduling marijuana from Schedule I to Schedule III. Schedules of

Controlled Substances: Rescheduling of Marijuana, 89 Fed. Reg. 44597, 44597 (May 21, 2024).

The Attorney General, rather than the DEA Administrator, signed the notice of proposed

rulemaking. See id. at 44622. According to press reporting, DEA has “long resisted”

rescheduling marijuana. Joshua Goodman & Jim Mustian, Top U.S. Drug Agency A Notable

Holdout in Biden’s Push to Loosen Federal Marijuana Restrictions, AP (May 20, 2024),

https://apnews.com/article/marijuana-pot-dea-legalization-biden-

cb7869d3286094f0124de728320d89c1.

Following the rulemaking notice, the DEA appointed an administrative law judge to

oversee a formal rulemaking process and named a 25-member panel of marijuana groups and

2 experts to participate in the hearings. Mot. at 4. That panel includes Smart Approaches to

Marijuana (“SAM”), a group opposed to rescheduling. Id. at 3. Hearings are scheduled to begin

on January 21, 2025, and run through March 6, 2025. Mot. Reply, Ex. 7 at 6.

B. Zorn’s FOIA Request

About one week before DOJ published notice of the proposed rulemaking, Dr. Kevin

Sabet, who is affiliated with SAM, posted on social media that the DEA Administrator “did NOT

sign the rescheduling order, breaking with five decades of precedent and established law and

regulations[.]” Mot. at 3. As support, Dr. Sabet cited “two confidential sources inside DEA and

another outside DEA[.]” Id. When someone asked Dr. Sabet how he knew about the

Administrator’s refusal in advance, he posted that he had “friends in low places.” Id.

Rescheduling proponents took these posts to mean that someone at DEA had engaged in

improper ex parte contacts with Dr. Sabet. Two groups raised this issue with the presiding ALJ

and asked him to “remov[e] the DEA and its Administrator as the sponsor and proponent of the

proposed rescheduling action” and for other relief. Compl., Ex. 3 at 1–2. The ALJ denied that

motion, explaining that while he found the allegations “distasteful,” he lacked authority to grant

the relief sought. Id. at 2. The ALJ also viewed the record as insufficient to conclude that “the

agency’s decisonmaking process has been or would be irrevocably tainted so as to make the

ultimate judgment of the agency unfair[.]” Id. at 7 (cleaned up).

Zorn tried a different approach and filed a FOIA request with DEA seeking emails related

to the purported contacts. Specifically, he requested all DEA emails between October 1, 2022,

and October 29, 2024, with the following keywords:

3 1. Marijuana; AND

2. Rescheduling or proceeding; AND

3. Sabet OR “smart approaches for marijuana” OR SAM OR Torridon OR Niforatos OR kevin OR barr OR shea

Mot. at 4–5. (“Torridon,” “Niforatos,” “Barr,” and “Shea” refer to other individuals or entities

affiliated with SAM. Opp’n at 3–4.) After DEA did not respond, Zorn filed this lawsuit and

moved for a preliminary injunction. DEA then denied Zorn’s FOIA request and opposed the

preliminary injunction on the ground that Zorn’s initial request was unduly burdensome. Id. at

1–2. In response, Zorn proposed narrowing his FOIA request to emails “from those DEA

employees engaged in the ex parte contacts.” Mot. Reply at 2.

The government then moved for summary judgment and filed a declaration supporting its

undue-burden arguments. Because Zorn has filed an amended complaint, the Court will deny the

government’s motion as moot and permit the government to file another responsive pleading

within 30 days of the amended complaint. The Court will, however, construe the government’s

motion as a sur-reply for purposes of Zorn’s preliminary-injunction motion and consider the

arguments contained therein and the supporting declaration. See 11A Fed. Prac. & Proc. Civ.

§ 2949 (“Affidavits are appropriate on a preliminary-injunction motion and typically will be

offered by both parties.”).

II. Legal Standard

“A preliminary injunction is an extraordinary remedy never awarded as of right.” Winter

v. Nat. Res. Def. Council, 555 U.S. 7, 24 (2008). A party seeking such relief must, “by a clear

showing, carr[y] the burden of persuasion” and demonstrate “(1) a substantial likelihood of

success on the merits, (2) that it would suffer irreparable injury if the injunction were not

granted, (3) that an injunction would not substantially injure other interested parties, and (4) that

4 the public interest would be furthered by the injunction.” Chaplaincy of Full Gospel Churches v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Zorn v. U.S. Department of Justice, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zorn-v-us-department-of-justice-dcd-2025.